Harshad S. Ugamraj
Harshad S. Ugamraj publishes mostly in Radiology, Nuclear Medicine and Imaging, Oncology and Immunology, on topics such as Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research and Biosimilars and Bioanalytical Methods.
- World rank
- #2,177,098 of 7,710,434 ranked researchers
- Rank in United States
- #654,197 of 1,627,098
- Works
- 22
- Citations
- 430
- Citations per work
- 19.5
What does Harshad S. Ugamraj research?
Harshad S. Ugamraj's work is mostly in Medicine (57%), Biochemistry, Genetics and Molecular Biology (19%), Immunology and Microbiology (16%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1357.1%
- Medicine1357.1%
- Life Sciences835.0%
- Everything else27.9%
- 1Radiology, Nuclear Medicine and Imaging32% of their works
- 2Oncology25% of their works
- 3Immunology16% of their works
- 4Molecular Biology10% of their works
- 5Biotechnology5% of their works
- 6Physiology5% of their works
Research topics
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Calcium signaling and nucleotide metabolism
- Toxin Mechanisms and Immunotoxins
- Radiopharmaceutical Chemistry and Applications
Which keywords describe Harshad S. Ugamraj's research?
The keywords of their largest research topics: Monoclonal Antibodies, Glycosylation, Fc Receptors, Therapeutic Antibodies, Immunotherapy, Tumor Regression, CAR T Cells and Chimeric Antigen Receptor.
- Tumor Targeting
- Radiopharmaceuticals
- Lysosomal Calcium Signaling
- Bacterial Therapy
- Glycans
- Immunogenicity
- Chimeric Antigen Receptor
- Tumor Regression
- Therapeutic Antibodies
- Glycosylation
- Monoclonal Antibodies
- Fc Receptors
- Immunotherapy
- CAR T Cells
- Biosimilars
- Cancer
- Targeted Therapy
- Immunotoxin
- PET Imaging
- Ricin Poisoning
- Two-pore Channels
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Monoclonal Antibodies242 topics
- Glycosylation222 topics
- Fc Receptors181 topic
- Therapeutic Antibodies181 topic
- Immunotherapy172 topics
- Tumor Regression172 topics
- CAR T Cells151 topic
- Chimeric Antigen Receptor151 topic
- Biosimilars61 topic
- Immunogenicity61 topic
- Cancer41 topic
- Glycans41 topic
- Targeted Therapy42 topics
- Bacterial Therapy21 topic
- Immunotoxin21 topic
- Lysosomal Calcium Signaling21 topic
- PET Imaging21 topic
- Radiopharmaceuticals21 topic
- Ricin Poisoning21 topic
- Tumor Targeting21 topic
- Two-pore Channels21 topic
Where does Harshad S. Ugamraj work?
Harshad S. Ugamraj's main affiliation in the publication record is Tenneco (United States), United States.
How many publications and citations does Harshad S. Ugamraj have?
OpenAlex counts 22 works and 430 citations for Harshad S. Ugamraj, an h-index of 9, ranking #2,177,098 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Harshad S. Ugamraj. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.